Cargando…
Prevalence of perennial severe allergic asthma in Italy and effectiveness of omalizumab in its management: PROXIMA – an observational, 2 phase, patient reported outcomes study
BACKGROUND: We designed the PROXIMA study (Patient-Reported Outcomes and Xolair(®) In the Management of Asthma) to determine the proportion of patients with severe asthma sensitive to perennial allergens, and to evaluate asthma control and treatment adherence up to 12 months in patients treated with...
Autores principales: | Canonica, Giorgio Walter, Bartezaghi, Marta, Marino, Raffaele, Rigoni, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494726/ https://www.ncbi.nlm.nih.gov/pubmed/26155196 http://dx.doi.org/10.1186/s12948-015-0019-7 |
Ejemplares similares
-
Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study
por: Canonica, Giorgio Walter, et al.
Publicado: (2018) -
Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis
por: Heffler, Enrico, et al.
Publicado: (2020) -
Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study
por: Canonica, Giorgio Walter, et al.
Publicado: (2020) -
Plasma Galectin-3 and urine proteomics predict FEV(1) improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study()
por: Riccio, Anna Maria, et al.
Publicado: (2020) -
Gender differences in asthma perception and its impact on quality of life: a post hoc analysis of the PROXIMA (Patient Reported Outcomes and Xolair(®) In the Management of Asthma) study
por: Colombo, Delia, et al.
Publicado: (2019)